Details:
Edirol® Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D3 preparation). Chugai manufactures Edirol Tablet and supplies to Towa.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Bonviva is a medicine that contains the active substance ibandronic acid. It is available as tablets (150 mg) and as a solution for injection in a prefilled syringe (3 mg).
Lead Product(s): Ibandronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Bonviva
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Taisho Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
CRYSVITA (burosumab) is a recombinant fully human monoclonal antibody that binds to and inhibits the activity of FGF23.2 CRYSVITA blocks the action of FGF23, which is produced in excess in TIO, restoring phosphate homeostasis.
Lead Product(s): Burosumab
Therapeutic Area: Musculoskeletal Product Name: Crysvita
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Edirol (eldecalcitol), is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research. Chugai takes responsibilities as a holder of the approval, Towa will be responsible for marketing and providing information on use of Edirol.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Towa Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.
Lead Product(s): Dotinurad
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fortress Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 10, 2021
Details:
Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2021
Details:
Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
The facility, previously owned by Daiichi Sankyo Europe, an affiliate of American Regent, produces the API for Adequan®i.m. and Adequan® Canine.
Lead Product(s): Polysulfated glycosaminoglycan
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: American Regent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2020